Annual report
7634.TEDINET S100W5LL
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥14.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥13.8bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.3bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥994m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥24.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥23.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥21.2bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥20.3bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥19.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.9bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥17.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥15.6bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥14.5bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥13.5bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.0bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.7bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥745m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥690m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥740m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥903m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥958m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥937m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥469.18 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥450.7 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥402.98 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥358.33 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥313.14 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5,900.59 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,481.61 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,931.68 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,594.54 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,289.53 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 74.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.3% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 500 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 486 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 470 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 439 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 431 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥14.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥12.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥11.8bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥10.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥10.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.8bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥1.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.9bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.6bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.8bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.8bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.1bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥971m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥890m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥23.5bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥20.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥19.1bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥18.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥17.2bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.2bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥5.2bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥17.3bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥15.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥13.8bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥12.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥11.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥9.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥713.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥387.91 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥350.09 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥314.16 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥280.41 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥70 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥5,554.25 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,877.89 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,422.06 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,123.08 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,855.53 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 73.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.1% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.7% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,420,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 428 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 339 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 334 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 313 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 305 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 102
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥72m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥141m |
| Care Welfare Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥48m |
| Care Welfare Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥19m |
| Care Welfare Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | segment assets | at 2025-03-31 | ¥350m |
| Care Welfare Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥44m |
| Home Medical Treatment Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥900m |
| Home Medical Treatment Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥592m |
| Home Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.7bn |
| Home Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.7bn |
| Home Medical Treatment Relatedreportable segment | segment assets | at 2025-03-31 | ¥2.6bn |
| Home Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥907m |
| Medical Gas Equipment Installation Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥22m |
| Medical Gas Equipment Installation Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥9m |
| Medical Gas Equipment Installation Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥86m |
| Medical Gas Equipment Installation Relatedreportable segment | segment assets | at 2025-03-31 | ¥284m |
| Medical Gas Equipment Installation Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥272m |
| Medical Gas Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥325m |
| Medical Gas Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥146m |
| Medical Gas Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Medical Gas Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Medical Gas Relatedreportable segment | segment assets | at 2025-03-31 | ¥1.7bn |
| Medical Gas Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥636m |
| Nursing Homereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥19m |
| Nursing Homereportable segment | employees | at 2025-03-31 | 42 pure |
| Nursing Homereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥331m |
| Nursing Homereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥331m |
| Nursing Homereportable segment | segment assets | at 2025-03-31 | ¥1.2bn |
| Nursing Homereportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥18m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥785m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥14.2bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥14.1bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥86m |
| —segment total | segment assets | at 2025-03-31 | ¥6.1bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥787m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥15.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥15.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥86m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥71m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥151m |
| Care Welfare Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥25m |
| Care Welfare Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥20m |
| Care Welfare Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | segment assets | at 2024-03-31 | ¥351m |
| Care Welfare Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥40m |
| Home Medical Treatment Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥581m |
| Home Medical Treatment Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥673m |
| Home Medical Treatment Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥6.3bn |
| Home Medical Treatment Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.3bn |
| Home Medical Treatment Relatedreportable segment | segment assets | at 2024-03-31 | ¥2.3bn |
| Home Medical Treatment Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥800m |
| Medical Gas Equipment Installation Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥15m |
| Medical Gas Equipment Installation Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥9m |
| Medical Gas Equipment Installation Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥87m |
| Medical Gas Equipment Installation Relatedreportable segment | segment assets | at 2024-03-31 | ¥282m |
| Medical Gas Equipment Installation Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥344m |
| Medical Gas Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥176m |
| Medical Gas Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥142m |
| Medical Gas Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Medical Gas Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Medical Gas Relatedreportable segment | segment assets | at 2024-03-31 | ¥1.5bn |
| Medical Gas Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥609m |
| Nursing Homereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥19m |
| Nursing Homereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥350m |
| Nursing Homereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥350m |
| Nursing Homereportable segment | segment assets | at 2024-03-31 | ¥1.2bn |
| Nursing Homereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥17m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥797m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥863m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥13.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥13.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥87m |
| —segment total | segment assets | at 2024-03-31 | ¥5.6bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥800m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥865m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥87m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Nursing Homereportable segment | employees | at 2025-03-31 | 42 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,581
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | Prior1YearDuration | -211000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | － | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -201927000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -217546000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -902905000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -739640000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 747690000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -3834589000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 8991480000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 9755745000 | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | Prior1YearDuration | － | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | CurrentYearDuration | 4662000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YearDuration | 16574000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYearDuration | － | JPY |
| Cash and cash equivalents | Prior1YearInstant | 9755745000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 5925818000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 5 | |
| Notes receivable trade | Prior1YearInstant | 388687000 | JPY |
| Notes receivable trade | CurrentYearInstant | 264246000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 2335679000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 2607244000 | JPY |
| Contract assets | Prior1YearInstant | 86417000 | JPY |
| Contract assets | CurrentYearInstant | － | JPY |
| Contract liabilities | Prior1YearInstant | 94974000 | JPY |
| Contract liabilities | CurrentYearInstant | 71913000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 7692000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 7870000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03330-000MedicalGasRelatedReportableSegmentsMember | 3825291000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03330-000HomeMedicalTreatmentRelatedReportableSegmentsMember | 6305819000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03330-000MedicalGasEquipmentInstallationRelatedReportableSegmentsMember | 2056532000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03330-000CareWelfareRelatedReportableSegmentsMember | 1211464000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03330-000NursingHomeReportableSegmentsMember | 349989000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 13749097000 | JPY |
| Revenues from external customers | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1029113000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 14778211000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03330-000MedicalGasRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03330-000HomeMedicalTreatmentRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03330-000MedicalGasEquipmentInstallationRelatedReportableSegmentsMember | 86771000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03330-000CareWelfareRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03330-000NursingHomeReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 86771000 | JPY |
| Transactions with other segments | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 86771000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E03330-000MedicalGasRelatedReportableSegmentsMember | 3825291000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E03330-000HomeMedicalTreatmentRelatedReportableSegmentsMember | 6305819000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E03330-000MedicalGasEquipmentInstallationRelatedReportableSegmentsMember | 2143303000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E03330-000CareWelfareRelatedReportableSegmentsMember | 1211464000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E03330-000NursingHomeReportableSegmentsMember | 349989000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 13835868000 | JPY |
| Net sales | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1029113000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |